A Pilot Prevention Study of the Effects of the Anti-progestin Ulipristal Acetate (UA) on Surrogate Markers of Breast Cancer Risk

Trial Profile

A Pilot Prevention Study of the Effects of the Anti-progestin Ulipristal Acetate (UA) on Surrogate Markers of Breast Cancer Risk

Completed
Phase of Trial: Phase II

Latest Information Update: 05 Oct 2017

At a glance

  • Drugs Ulipristal (Primary)
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Acronyms BC-APPS1
  • Most Recent Events

    • 05 Oct 2017 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently (last verified Oct 2015).
    • 01 Oct 2017 Status changed from active, no longer recruiting to completed.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top